I begge undersøgelser havde Tasigna en lignende virkning hos patienter, hvor imatinib ikke tolereredes eller ikke længere virkede på sygdommen.
In both studies, Tasigna had a similar effect in patients who could not tolerate imatinib and those whose disease had stopped responding to it.